Cambridge Investment Research Advisors, Inc. Bluebird Bio, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$11.24 - $21.0 $153,189 - $286,209	-13,629 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$18.04 - $22.09 $8,478 - $10,382	-470 Reduced 3.33%	13,629 $282,000
Q1 2021 May 07, 2021	BUY	$16.59 - $33.89 $28,783 - $58,799	1,735 Added 14.03%	14,099 $275,000
Q4 2020 Feb 04, 2021	SELL	$27.5 - $37.92 $215,297 - $296,875	-7,829 Reduced 38.77%	12,364 $346,000
Q3 2020 Oct 29, 2020	BUY	$34.44 - $43.75 $340,783 - $432,906	9,895 Added 96.09%	20,193 $705,000
Q2 2020 Jul 27, 2020	BUY	$27.12 - $45.97 $18,034 - $30,570	665 Added 6.9%	10,298 $407,000
Q1 2020 May 08, 2020	BUY	$26.16 - $63.5 $251,999 - $611,695	9,633 New	9,633 $286,000
Q2 2019 Aug 15, 2019	SELL	$75.84 - $105.21 $124,377 - $172,544	-1,640 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$64.44 - $104.11 $105,681 - $170,740	1,640 New	1,640 $0
Q4 2018 Feb 05, 2019	SELL	$59.1 - $93.26 $96,924 - $152,946	-1,640 Closed	0 $0
Q3 2018 Nov 02, 2018	BUY	$88.86 - $117.49 $145,730 - $192,683	1,640 New	1,640 $0
Q2 2018 Aug 10, 2018	SELL	$99.64 - $127.59 $135,908 - $174,032	-1,364 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$105.8 - $150.94 $144,311 - $205,882	1,364 New	1,364 $0

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.67 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.64 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.63 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.34 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account